Company intelligence / Profile preview

Seneca Therapeutics

King of Prussia, Pennsylvania, USA

Ownership: Private
Development stage: Phase 2

Overview

SVV-001 has shown promising activity in clinical studies conducted in patients having tumors of neuroendocrine origin, including small cell lung cancer. The company is preparing for a Phase 1 trial of SVV-001 in combination with Nivolumab and Ipilimumab in patients with neuroendocrine tumors.

Therapeutic areas: Oncology
Modalities: Oncolytic virus immunotherapy
Industry: Biotech

Drug pipeline

7 assets

SVV-005

Preclinical

6 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Seneca Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seneca Therapeutics.

Explore the full profile